Meijers CEO John K. Miller says he supports a “complete cessation” of flu shots for people in the U.S. but also believes that there are “good reasons to get them every two weeks.”
Miller said Monday that Meijes decision to stop selling flu vaccines is part of the company’s larger effort to reduce vaccine-preventable illness.
The flu vaccine is the only flu vaccine that Meiji can still produce.
In addition to Meijel and its other pharmacies, Meijen has a large distribution network in the United States.
The influenza pandemic began in mid-March, forcing the shutdown of many Meijermax pharmacies.
Miller said in a statement that he is “encouraged that there has been a reduction in the number of people who are experiencing flu-like symptoms.”
The statement said Meijeros goal is to “ensure that Mejis influenza vaccines remain available to those who need them most.”
Miller’s comments follow comments by his boss, CEO John Miller, in a recent interview with The Associated Press.
The chief executive said the flu vaccine has “served its purpose,” and that the company is moving forward.
“It is not a complete cessation of flu vaccinations,” Miller said.
“We believe that the vaccine remains the best way to protect the U, and we remain committed to working with the Centers for Disease Control and Prevention to reduce the burden of influenza.”
Miller did not mention Meijeans flu vaccine or the potential for an additional shutdown of the U’s flu vaccines, but he did not directly address the possibility of further flu vaccinations for people who need the vaccines.
Miller also defended Meijens decision to end the flu vaccines.
In a statement, Meiji said it is working to ensure that its flu vaccine can continue to be produced as planned.
Meijer announced the end of flu vaccination on April 6, two days after it announced it would halt production.
The move has not been met with universal acclaim from vaccine advocates and health officials.
The Centers for Diseases Control and the Food and Drug Administration say that Meixis flu vaccine continues to work in a number of settings and that more studies are needed to evaluate the effectiveness of Meijin’s flu vaccine.